Opko Signs Deals to Place $30M in Stock, Warrants | GenomeWeb

Opko Health said this week that it has entered into definitive agreements to privately place $30 million in preferred stock and warrants.

As part of the transaction, the company will issue roughly 1.2 million shares of an 8 percent Series D Cumulative Convertible Preferred Stock at a purchase price of $24.80 per share, and warrants to purchase an aggregate of approximately 3 million shares of its common stock.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions.

Ancestry.com is eyeing an expansion into genomic risk assessments, the Verge reports.